Opus Genetics Inc. Ordinary Shares IRD 深 沪
已收盘 08-01 16:00:00 美东时间
1.07
-0.040
-3.60%
华盛通- 最 高1.129
- 今 开1.12
- 成交量 14.00万股
- 最 低 1.0694
- 昨 收 1.11
- 总市值 6383.75万
- 52周最高 1.75
- 市盈率 静 --
- 换手率 0.23%
- 52周最低 0.65
- 委 比 95.01%
- 总股本 5966.12万
- 历史最高 23.08
- 量 比 0.91
- 振 幅 5.37%
- 历史最低 0.65
- 每 手 1
- 风险率 0.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多AMGEN ANNOUNCES 2025 THIRD QUARTER DIVIDEND
THOUSAND OAKS, Calif., Aug. 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the third quarter of 2025. The div...
08-02 04:01
Shell Guides Q3 LNG Output At 6.7–7.3M Tonnes, Upstream At 1.7–1.9M boe/d; Sees Corporate Loss Of $500M–$700M And 2025 Capex At $20B–$22B
OUTLOOK FOR THE THIRD QUARTER 2025 Full year 2024 cash capital expenditure was $21 billion. Our cash capital expenditure range for the full year 2025 is expected to be within $20 - $22 billion. Integrated Gas
07-31 14:16
Analysts Are Bullish on Top Healthcare Stocks: Viking Therapeutics (VKTX), Opus Genetics (IRD)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
07-24 18:20
Opus Genetics Secures Funding for Gene Therapy Development
Opus Genetics ( ($IRD) ) has shared an announcement. On July 22, 2025, Opus Gen...
07-23 20:50
Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness
Opus Genetics collaborates with the Global RDH12 Alliance to advance its OPGx-RDH12 gene therapy for treating RDH12-related Leber congenital amaurosis (RDH12-LCA). The partnership aims to accelerate development, with $1.6 million funding from the Alliance and target IND filing by late 2025. The collaboration combines patient insights with Opus' expertise, aiming to restore vision for RDH12-LCA patients. Preclinical studies show promising results,...
07-23 12:00
CIVISTA BANCSHARES, INC. DECLARES THIRD QUARTER COMMON DIVIDEND
SANDUSKY, Ohio, July 22, 2025 /PRNewswire/ -- Civista Bancshares, Inc. (NASDAQ:CIVB) ("Civista") announced today that the Board of Directors has approved a quarterly dividend of 17 cents per...
07-23 04:50
Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review
Viatris' Phase 3 trial for pimecrolimus 0.3% in blepharitis did not meet its primary goal, prompting the company to reassess its development strategy.
07-19 02:17
Bajaj Finserv Gains IRDAI Approval for Allianz Stake Acquisition
Bajaj Finserv Limited ( ($IN:BAJAJFINSV) ) has provided an announcement. Bajaj ...
07-16 11:45
Discover Opportunities to Buy International Homes at the Global Property Expo, Singapore
SINGAPORE, July 14, 2025 /PRNewswire/ -- For Singaporeans envisioning buying a residential property abroad, the Global Property Expo organised by JLL (NYSE: JLL) offers an unparalleled oppor...
07-14 12:22
Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>Opus Genetics, a biopharmaceutical company developing gene and small molecule therapies for vision-threatening eye diseases, announced it granted equity awards totaling 240,000 stock options and 150,000 RSUs to two new non-executive employees under the 2021 Inducement Plan. The stock options have an exercise price of $0.94 and vest over four years, while RSUs vest annually over four years. Both awards are contingent on continued employment. Th...
07-03 20:30
